Horizon Strengthens Board with Appointment of Dr. Ian Gilham
News Aug 02, 2013
Horizon Discovery (Horizon) has announced the appointment of Dr. Ian Gilham as a non-executive director.
Ian is currently non-executive chairman of Multiplicom NV, focused on the development and commercialization of DNA sequencing products; and Biosurfit SA, focused on development and commercialization of point-of-care diagnostic products.
He is also Director of Stowheath Ltd., which offers advisory services to private equity companies and corporate finance organizations investing in clinical diagnostics and medical device companies.
Ian has previously been CEO of Axis-Shield plc and Vice President, Pharmacogenetics and Diagnostics at GSK, as well as holding various positions within Abbott Laboratories.
Commenting on the announcement, Dr. Darrin M Disley, CEO of Horizon said: “I would like to welcome Ian to Horizon’s board of directors. His commercial and investor relations experience will be highly valuable to the company as we continue to develop as a world-leading translational genomics organization.”
Dr. Gilham noted: “Horizon is one of the UK’s most promising life science companies. I’m delighted to join the board at this stage of the organization’s development.”
Horizon’s mission is to provide its customers with cutting-edge biological tools and services that will accelerate the pace of development of ‘personalized’ medicines.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.